Arcadia Biosciences (NASDAQ:RKDA) Receiving Somewhat Favorable News Coverage, Analysis Finds

News headlines about Arcadia Biosciences (NASDAQ:RKDA) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Arcadia Biosciences earned a news sentiment score of 0.06 on Accern’s scale. Accern also gave news stories about the basic materials company an impact score of 45.2077264915636 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Separately, Piper Jaffray Companies set a $1.00 price objective on Arcadia Biosciences and gave the stock a “hold” rating in a report on Saturday, July 22nd.

Arcadia Biosciences (NASDAQ RKDA) traded down 11.2336% on Tuesday, hitting $0.3461. The stock had a trading volume of 142,608 shares. Arcadia Biosciences has a 1-year low of $0.30 and a 1-year high of $1.95. The firm’s market capitalization is $14.77 million. The stock’s 50-day moving average is $0.42 and its 200 day moving average is $0.56.

Arcadia Biosciences (NASDAQ:RKDA) last issued its earnings results on Thursday, August 10th. The basic materials company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.02. Arcadia Biosciences had a negative net margin of 499.59% and a negative return on equity of 87.43%. The company had revenue of $0.99 million for the quarter. On average, equities research analysts predict that Arcadia Biosciences will post ($0.36) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was published by BBNS and is the sole property of of BBNS. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://baseballnewssource.com/markets/arcadia-biosciences-rkda-getting-somewhat-favorable-media-coverage-analysis-finds/1699582.html.

About Arcadia Biosciences

Arcadia Biosciences, Inc is an agricultural biotechnology trait company. The Company develops a portfolio of yield and traits addressing multiple crops that supply the global food and feed markets. It has a pipeline of products in development incorporating its traits, including products that are in advanced stages of development or on the market.

Insider Buying and Selling by Quarter for Arcadia Biosciences (NASDAQ:RKDA)

Receive News & Ratings for Arcadia Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell


Leave a Reply

 
© 2006-2017 BBNS.